Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCND3 | P30281 | 3/20 | 0.34 |
| ▸ | CDK7 | P50613 | 3/20 | 0.34 |
| ▸ | CDK9 | P50750 | 3/20 | 0.34 |
| ▸ | CCNH | P51946 | 3/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872162 | 0.80 | EIF4A3 (0.33) | EIF4A3 | |
| SCHEMBL20049240 | 0.78 | EIF4A3 (0.33) | EIF4A3 | |
| SCHEMBL20043186 | 0.78 | KCNH2 (0.34) | CCNA2CDK2CDK5CDK5R1KCNH2 | |
| SCHEMBL9220628 | 0.74 | TERT (0.41) | KCNH2HRH3 | |
| SCHEMBL20047702 | 0.74 | EIF4A3 (0.33) | CCR4EIF4A3 | |
| SCHEMBL14072407 | 0.73 | NPC1 (0.38) | KCNH2HRH3EIF4A3 | |
| SCHEMBL10024929 | 0.71 | PSMB5 (0.40) | KCNH2HRH3EIF4A3 | |
| SCHEMBL21161221 | 0.71 | KCNH2 (0.31) | KCNH2HRH3 | |
| SCHEMBL10220179 | 0.70 | BACE1 (0.53) | KCNH2HRH3 | |
| SCHEMBL21161371 | 0.70 | PDE2A (0.37) | KCNH2EIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CCNT1 4836/4885CCNA2 4854/4885CDK2 4501/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CCNT1 4836/4885CCNA2 4854/4885CDK2 4501/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CCNT1 4836/4885CCNA2 4854/4885CDK2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.